Method of enhancing the expression of apolipoprotein AI using olefin derivatives
Compounds having an activity to enhance the expression of apoAI are provided. Compounds of formula (I): in which Ar 1 and Ar 2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic heterocyclic group, which may be optionally substituted; —X— is —N═CZ 2 —, —CY 2 ═CZ 2 —, —CY 2 Y 3 —CHZ 2 —, —S—, —O—, or the like; Y 1 , Y 2 , Y 3 , Z 1 and Z 2 are independently a hydrogen, a halogen, a lower alkyl, a phenyl, or the like; Z 1 and Z 2 may be independently a linker group that may combine with Ar 2 and Ar 1 to form a condensed ring; m is 0 or 1, and n is 0 to 2; a prodrug thereof, a pharmaceutically acceptable salt or solvate thereof; are disclosed.
1. A method of enhancing the expression of apoAI, which comprises administrating a compound of formula (I):
in which
Ar 1 and Ar 2 are independently phenyl, or a monocyclic or bicyclic aromatic heterocyclic group, wherein said groups are optionally substituted with a substituent selected from the group consisting of halogen; hydroxy; lower alkyl optionally substituted with halogen, hydroxy, or lower alkoxy; lower alkoxy optionally substituted with halogen, hydroxy, carboxy, or lower alkoxycarbonyl; lower alkenyl optionally substituted with halogen or hydroxy; lower alkenyloxy optionally substituted with halogen or hydroxy; lower alkylthio; non-aromatic carbocyclic group optionally substituted with halogen, hydroxy, or lower alkyl; acyl; acyloxy; carboxy; lower alkoxycarbonyl; lower alkenyloxycarbonyl; amino optionally substituted with lower alkyl or acyl; hydrazino; nitro; cyano; phenyl or naphthyl optionally substituted with halogen, hydroxy, lower alkyl or lower alkoxy; a heterocyclic group; phenoxy optionally substituted with halogen, hydroxy, or lower alkyl; a monocyclic aromatic heterocyclic oxy; oxo; and alkylenedioxy optionally substituted with lower alkyl, lower alkoxy, or phenyl;
—X— is a group of formula (α):
wherein
the broken line is the presence or absence of a bond;
-Q= is a group of
when the broken line is the presence of a bond;
the wavy line represents a cis- or trans-geometrical isomerism with respect to the double bond; and
-Q- is —CY 2 Y 3 — or —NY 4 — when the broken line is the absence of a bond; or —X— is -β- wherein -β- is —CY 2 Y 3 —, —NY 4 —, —S— or —O—;
Y 1 , Y 2 , Y 3 , Z 1 and Z 2 are independently hydrogen, halogen, lower alkyl, carboxy, lower alkoxycarbonyl, a monocyclic carbocyclic group, or a monocyclic heterocyclic group, wherein said lower alkyl and lower alkoxycarbonyl are optionally substituted with a substituent selected from the group consisting of halogen, hydroxy, lower alkoxy, a monocyclic or bicyclic carbocyclic group, acyl, acyloxy, carboxy, lower alkoxycarbonyl, amino, lower alkylamino, nitro, and a monocyclic or bicyclic heterocyclic group, wherein said monocyclic carbocyclic group and said monocyclic heterocyclic group are optionally substituted with a substituent selected from the same group as the substituent of phenyl described above, and two Y 1 s or more and two Z 1 s or more each may be different one another;
Y 4 is hydrogen or lower alkyl;
m is 0 or 1;
n is 0, 1, or 2; provided that, when n is 0, then m is 1 and —X— is a group of formula (α);
the wavy line represents a cis- or trans-geometrical isomerism with respect to the double bond;
provided that:
(a) when both Ar 1 and Ar 2 are substituted or unsubstituted phenyl, then none of Y 1 , Y 2 , Z 1 and Z 2 can be substituted or unsubstituted phenyl; or
(b) when either Ar 1 or Ar 2 is substituted phenyl, the substituent is independently selected from the group consisting of halogen; lower alkyl optionally substituted with halogen, hydroxy, or lower alkoxy; lower alkenyl optionally substituted with halogen or hydroxy; lower alkenyloxy optionally substituted with halogen or hydroxy; lower alkylthio; non-aromatic carbocyclic group optionally substituted with halogen, hydroxy, or lower alkyl; acyl; acyloxy; carboxy; lower alkoxycarbonyl; lower alkenyloxycarbonyl; amino optionally substituted with lower alkyl or acyl; hydrazino, nitro; cyano; phenyl or naphthyl optionally substituted with halogen, hydroxy, lower alkyl or lower alkoxy; a heterocyclic group; a monocyclic aromatic heterocyclic oxy; oxo; and alkylenedioxy optionally substituted with lower alkyl, lower alkoxy, or phenyl;
or a pharmaceutically acceptable salt thereof,
to a patient who needs treatment of dyslipidemia or arteriosclerotic diseases.
2. The method according to claim 1 , in which at least one of Ar 1 and Ar 2 in formula (I) is a monocyclic or bicyclic aromatic heterocyclic group that may be optionally substituted, and that contains a nitrogen atom at the position adjacent to the constituent atom of the ring that has a binding bond.
3. The method according to claim 1 , in which at least one of Ar 1 and Ar 2 in formula (I) is 2-pyridyl, 2-quinolyl, 2-quinoxalyl, 2-benzisoxazolyl, 2-benzothiazolyl, or 2-benzimidazolyl, each of which may be optionally substituted.
4. The method according to claim 2 or 3 , in which one of Ar 1 and Ar 2 in formula (I) is a group as defined in claim 2 or 3 , and the other is a phenyl that may be optionally substituted, or a monocyclic or bicyclic aromatic heterocyclic group that may be optionally substituted.
5. The method according to claim 2 or 3 , in which one of Ar 1 and Ar 2 in formula (I) is a group as defined in claim 2 or 3 , and the other is a phenyl or a monocyclic or bicyclic aromatic heterocyclic group, each of which may be optionally substituted, wherein the substituent is a halogen; a lower alkyl optionally substituted by a halogen or a lower alkoxy; a hydroxy; a lower alkoxy; a phenyloxy; a naphtylthio; an acyloxy; a carboxy; a lower alkoxycarbonyl; an amino optionally substituted by a lower alkyl or a lower acyl; a phenyl that may be optionally substituted by a lower alkoxy; a nitro; a lower alkylthio; a cyano; a monocyclic heterocyclic group; or an alkylenedioxy that may be substituted by a lower alkyl, a lower alkoxy or phenyl.
6. The method according to any one of claims 1 to 3 , in which Y 1 , Y 2 , Y 3 , and Y 4 in formula (I) is a hydrogen.
7. The method according to any one of claims 1 to 3 , in which Z 1 , and Z 2 in formula (I) is a hydrogen.
8. The method according to any one of claims 1 to 3 , in which m in formula (I) is 1, —X— is a group of formula (α), the broken line is the presence of a bond, -Q= is a group of
and
Y 2 is a hydrogen.
9. The method according to any one of claims 1 to 3 , in which m and n in formula (I) are 1, and —X— is -β-.
10. The method according to claim 4 , in which Y 1 , Y 2 , Y 3 , and Y 4 in formula (I) is a hydrogen.
11. The method according to claim 5 , in which Y 1 , Y 2 , Y 3 , and Y 4 in formula (I) is a hydrogen.
12. The method according to claim 4 , in which Z 1 , and Z 2 in formula (I) is a hydrogen.
13. The method according to claim 5 , in which Z 1 , and Z 2 in formula (I) is a hydrogen.
14. The method according to claim 6 , in which Z 1 , and Z 2 in formula (I) is a hydrogen.
15. The method according to claim 4 , in which Z 1 in formula (I) is a linker group comprising 1 to 2 atoms that combines with the constituent atoms of the ring Ar 2 that are bonded to Z 1 via the two atoms to form a condensed ring.
16. The method according to claim 5 , in which Z 1 in formula (I) is a linker group comprising 1 to 2 atoms that combines with the constituent atoms of the ring Ar 2 that are bonded to Z 1 via the two atoms to form a condensed ring.
17. The method according to claim 6 , in which Z 1 in formula (I) is a linker group comprising 1 to 2 atoms that combines with the constituent atoms of the ring Ar 2 that are bonded to Z 1 via the two atoms to form a condensed ring.
18. The method according to claim 4 , in which m in formula (I) is 1, —X— is a group of formula (α), the broken line is the presence of a bond, -Q= is a group of
and
Y 2 is a hydrogen.
19. The method according to claim 5 , in which m in formula (I) is 1, —X— is a group of formula (α), the broken line is the presence of a bond, -Q= is a group of
and
Y 2 is a hydrogen.
20. The method according to claim 6 , in which m in formula (I) is 1, —X— is a group of formula (α), the broken line is the presence of a bond, -Q= is a group of
and
Y 2 is a hydrogen.
21. The method according to claim 7 , in which m in formula (I) is 1, —X— is a group of formula (α), the broken line is the presence of a bond, -Q= is a group of
and
Y 2 is a hydrogen.
22. The method according to claim 4 , in which m in formula (I) is 1, —X— is a group of formula (α), and Z 2 is a linker group comprising 1 to 2 atoms that combines with the constituent atoms of the ring Ar 1 to form a condensed ring.
23. The method according to claim 5 , in which m in formula (I) is 1, —X— is a group of formula (α), and Z 2 is a linker group comprising 1 to 2 atoms that combines with the constituent atoms of the ring Ar 1 to form a condensed ring.
24. The method according to claim 6 , in which m in formula (I) is 1, —X— is a group of formula (α), and Z 2 is a linker group comprising 1 to 2 atoms that combines with the constituent atoms of the ring Ar 1 to form a condensed ring.
25. The method according to claim 4 , in which m and n in formula (I) are 1, and —X— is -β-.
26. The method according to claim 5 , in which m and n in formula (I) are 1, and —X— is -β-.
27. The method according to claim 6 , in which m and n in formula (I) are 1, and —X— is -β-.
28. The method according to claim 7 , in which m and n in formula (I) are 1, and —X— is -β-.